Biotechnology

[ Cofactor Genomics raises $18M in Series A ]

Cofactor Genomics has raised $18 million in Series A funding. Founded in 2008, Cofactor Genomics is pioneering the use of RNA to diagnose disease. The comoany has developed key genomic and big data products that earned it contracts with eight of the largest pharmaceutical companies in the world. RNA takes genomics therapy a step further by

[ Genenta Science raises $8.4M in Series B ]

Genenta Science has raised $8.4 million in Series B funding. Founded in 2014, Genenta develops a gene transfer strategy into autologous hematopoietic stem cells (HSCs) to target specific antitumor proteins to tumor-infiltrating monocytes/macrophages. An HIV-derived and genetically disabled viral vector, Lentivirus delivers the gene into the HSCs. The companywill use the new money to advance its

[ DNA Script raises $13.19M in Series A ]

DNA Script has raised $13.19 million in Series A funding. Founded in 2014, DNA Script is focused on the manufacturing of synthetic DNA using a proprietary template-free enzymatic technology. The company aims at accelerating innovation in life science and technology through rapid, affordable and high quality DNA synthesis. With these funds and the support of major

[ Paragon Genomics raises $8M in Series A ]

Paragon Genomics has raised $8 million in Series A funding. Founded in 2015, Paragon Genomics was selected by a distinguished panel into the California Life Science Association F.A.S.T. Program in March 2016 and accepted into the prestigious Stanford StartX Accelerator Program in September 2016. Paragon is a life science company dedicated to improving critical upfront target

[ Sophia Genetics raises $30M in Series D ]

Sophia Genetics has raised $30 million in Series D funding. Founded in 2011, Sophia Genetics is a technology company which has developed SOPHiA, the most advanced collective artificial intelligence for clinical genomics, helping healthcare professionals better diagnose and treat patients. The new funding will be used to “fully deploy” Sophia’s SaaS platform globally, and to ramp

[ Freenome raises $7M in Series A ]

Freenome has raised $7 million in Series A funding. Founded in 2015, Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company has raised an additional $7 million as an extension to its previously announced Series A funding, bringing the total to nearly $72 million. Proceeds

[ ARMO Biosciences raises $67M in Series C ]

ARMO Biosciences has raised $67 million in Series C funding. Founded in 2013, ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The Series C-1 proceeds will be used to initiate phase 2/3 studies with ARMO’s lead immunotherapy agent AM0010 in non-small cell lung cancer and renal cell cancer and to support an

[ Akeso Biopharma raises $45.21M in Series B ]

Akeso Biopharma has raised $45.21 million in Series B funding. Founded in 2012, Akeso Biopharma has built a global level of bio-pharmaceutical research and development and industrialization platform; established for cancer, autoimmune diseases, inflammation and cardiovascular disease of the rich product line. The company plans to use the latest proceeds to support the development and clinical

[ MedGenome Inc. raises $30M in Series C ]

MedGenome Inc. has raised $30 million in Series C funding. Founded in 2013, MedGenome’s approach is twofold — on the one hand, it provides a range of genetic diagnostic tests in India, including prenatal, pediatric inherited disorders, and oncology testing. On the other hand, its lab in Silicon Valley offers sequencing platforms, bioinformatics, computing, and big

[ Quanterix raises $8.5M in Series D ]

Quanterix has raised $8.5 million in Series D funding. Founded in 2007, Quanterix develops and provides ultra-sensitive diagnostic solutions for brain injuries, cancer and heart diseases. The new financing is intended to be used to develop new instruments, expand the Company’s assay menu and meet global demand for the Company’s proprietary platform across therapeutic markets. Funding

Weekly Newsletter

Stay updated on VCs news

subscribe to our newsletter

News, data and statement included in FundingSMEs are intended exclusively for information purposes. No data or statement in FundingSMEs is or should be considered a recommendation for the purchase, retention, or sale of the securities referred to herein. FundingSMEs accepts no liability for the consequences of the reader's reliance on these news, data or statements and disclaims any intent to make securities or securities markets recommendations.

Note: It looks like JavaScript is disabled in your browser. Some elements of this form may require JavaScript to work properly. If you have trouble submitting the form, try enabling JavaScript momentarily and resubmit. JavaScript settings are usually found in Browser Settings or Browser Developer menu.